INTEGRAL ASSESSMENT OF FACTORS AFFECTING THE EFFECTIVENESS OF ACCOMPANYING IMMUNOTHERAPY IN ONCOGYNECOLOGICAL PATIENTS
Kamyshov S. V.*
According to our data, the overall 5-year survival rates in patients with cervical cancer II-III stages after complex therapy in combination with immunotherapy were as follows: in the group of patients receiving EIPT without plasmapheresis - 68.3 ± 5.4% (P = 0.037), in the group of patients receiving EIPHT with preliminary plasmapheresis - 72.3 ± 5.1% (P = 0.041) and in the control group without immunotherapy - 59.2 ± 4.2%. The parameters of the overall 5-year survival in patients with stage II-III ovarian cancer were: in the group receiving EIPHT without plasmapheresis - 72.1 ± 4.9% (P = 0.036), in the group receiving EIPHT with plasmapheresis - 73.5 ± 5.32% (P = 0.043) and in the control group without immunotherapy - 62.6 ± 5.0%. The analysis of the correlation of the tumor markers level and 5-year survival of patients allows to conclude that the positive level of p53, VEGF and Ki-67 in patients with cervical cancer and ovarian cancer, along with high proliferative activity of the tumor, may serve as a basis for this the category of patients accompanying immunotherapy with EIPHT, which can significantly increase the effectiveness of standard antitumor treatment regimens. At a positive level of oncomarkers, along with high proliferative activity of the tumor, it is possible to recommend carrying out accompanying immunotherapy with EIPHT with plasmapheresis.
Keywords: Oncogynecological diseases, ovarian cancer, cervical cancer, molecular-biological markers, proliferation.
[Full Text Article]